Tat‑thioredoxin 1 reduces inflammation by inhibiting pro‑inflammatory cytokines and modulating MAPK signaling

  • Authors:
    • Eun Ji Yeo
    • Min Jea Shin
    • Hyeon Ji Yeo
    • Yeon Joo Choi
    • Eun Jeong Sohn
    • Lee Re Lee
    • Hyun Jung Kwon
    • Hyun Ju Cha
    • Sung Ho Lee
    • Sunghou Lee
    • Yeon Hee Yu
    • Duk-Soo Kim
    • Dae Won Kim
    • Jinseu Park
    • Kyu Hyung Han
    • Won Sik Eum
    • Soo Young Choi
  • View Affiliations

  • Published online on: October 1, 2021     https://doi.org/10.3892/etm.2021.10831
  • Article Number: 1395
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Thioredoxin 1 (Trx1) serves a central role in redox homeostasis. It is involved in numerous other processes, including oxidative stress and apoptosis. However, to the best of our knowledge, the role of Trx1 in inflammation remains to be explored. The present study investigated the function and mechanism of cell permeable fused Tat‑Trx1 protein in macrophages and a mouse model. Transduction levels of Tat‑Trx1 were determined via western blotting. Cellular distribution of transduced Tat‑Trx1 was determined by fluorescence microscopy. 2',7'‑Dichlorofluorescein diacetate and TUNEL staining were performed to determine the production of reactive oxygen species and DNA fragmentation. Protein and gene expression were measured by western blotting and reverse transcription‑quantitative PCR (RT‑qPCR), respectively. Effects of skin inflammation were determined using hematoxylin and eosin staining, changes in ear weight and ear thickness, and RT‑qPCR in ear edema animal models. Transduced Tat‑Trx1 inhibited lipopolysaccharide‑induced cytotoxicity and activation of NF‑κB, MAPK and Akt. Additionally, Tat‑Trx1 markedly reduced the production of inducible nitric oxide synthase, cyclooxygenase‑2, IL‑1β, IL‑6 and TNF‑α in macrophages. In a 12‑O‑tetradecanoylphorbol‑13‑acetate‑induced mouse model, Tat‑Trx1 reduced inflammatory damage by inhibiting inflammatory mediator and cytokine production. Collectively, these results demonstrated that Tat‑Trx1 could exert anti‑inflammatory effects by inhibiting the production of pro‑inflammatory mediators and cytokines and by modulating MAPK signaling. Therefore, Tat‑Trx1 may be a useful therapeutic agent for diseases induced by inflammatory damage.
View Figures
View References

Related Articles

Journal Cover

December-2021
Volume 22 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yeo EJ, Shin MJ, Yeo HJ, Choi YJ, Sohn EJ, Lee LR, Kwon HJ, Cha HJ, Lee SH, Lee S, Lee S, et al: Tat‑thioredoxin 1 reduces inflammation by inhibiting pro‑inflammatory cytokines and modulating MAPK signaling. Exp Ther Med 22: 1395, 2021
APA
Yeo, E.J., Shin, M.J., Yeo, H.J., Choi, Y.J., Sohn, E.J., Lee, L.R. ... Choi, S.Y. (2021). Tat‑thioredoxin 1 reduces inflammation by inhibiting pro‑inflammatory cytokines and modulating MAPK signaling. Experimental and Therapeutic Medicine, 22, 1395. https://doi.org/10.3892/etm.2021.10831
MLA
Yeo, E. J., Shin, M. J., Yeo, H. J., Choi, Y. J., Sohn, E. J., Lee, L. R., Kwon, H. J., Cha, H. J., Lee, S. H., Lee, S., Yu, Y. H., Kim, D., Kim, D. W., Park, J., Han, K. H., Eum, W. S., Choi, S. Y."Tat‑thioredoxin 1 reduces inflammation by inhibiting pro‑inflammatory cytokines and modulating MAPK signaling". Experimental and Therapeutic Medicine 22.6 (2021): 1395.
Chicago
Yeo, E. J., Shin, M. J., Yeo, H. J., Choi, Y. J., Sohn, E. J., Lee, L. R., Kwon, H. J., Cha, H. J., Lee, S. H., Lee, S., Yu, Y. H., Kim, D., Kim, D. W., Park, J., Han, K. H., Eum, W. S., Choi, S. Y."Tat‑thioredoxin 1 reduces inflammation by inhibiting pro‑inflammatory cytokines and modulating MAPK signaling". Experimental and Therapeutic Medicine 22, no. 6 (2021): 1395. https://doi.org/10.3892/etm.2021.10831